The dopamine transporter (DAT) critically regulates the duration of the cellular actions of dopamine and the extent to which dopamine diffuses in the extracellular space. We sought to determine whether the reportedly greater diffusion of dopamine in the rat prefrontal cortex (PFC) as compared with the striatum is associated with a more restricted axonal distribution of the cortical DAT protein. By light microscopy, avidin–biotin–peroxidase immunostaining for DAT was visualized in fibers that were densely distributed within the dorsolateral striatum and the superficial layers of the dorsal anterior cingulate cortex. In contrast, DAT-labeled axons were distributed only sparsely to the deep layers of the prelimbic cortex. By electron microscopy, DAT-immunoreactive profiles in the striatum and cingulate cortex included both varicose and intervaricose segments of axons. However, DAT-labeled processes in the prelimbic cortex were almost exclusively intervaricose axon segments. Immunolabeling for tyrosine hydroxylase in adjacent sections of the prelimbic cortex was localized to both varicosities and intervaricose segments of axons. These qualitative observations were supported by a quantitative assessment in which the diameter of immunoreactive profiles was used as a relative measure of whether varicose or intervaricose axon segments were labeled. These results suggest that considerable extracellular diffusion of dopamine in the prelimbic PFC may result, at least in part, from a paucity of DAT content in mesocortical dopamine axons, as well as a distribution of the DAT protein at a distance from synaptic release sites. The results further suggest that different populations of dopamine neurons selectively target the DAT to different subcellular locations.

Key words: cingulate cortex; dopamine; dopamine transporter; prefrontal cortex; prelimbic; striatum; tyrosine hydroxylase

The dopamine transporter (DAT) is a crucial protein in the regulation of dopamine transmission, serving to remove dopamine from the extracellular space after its release. Studies in animals lacking expression of the DAT gene (Giros et al., 1996) suggest that this protein is perhaps the single most important determinant of the extraneuronal concentration and duration of dopamine. The DAT is also a protein of considerable clinical significance. For example, psychostimulant drugs of abuse block or reverse the action of the DAT and increase dopamine levels in key forebrain regions (Moghaddam and Bunney, 1989; Kuhar et al., 1991; Giros et al., 1996). Furthermore, DAT content in the basal ganglia is reduced significantly during the normal course of aging (Bannon et al., 1992) and in patients with Parkinson’s disease (Niznik et al., 1991; Harrington et al., 1996). The DAT has also been implicated as a potential site for uptake of environmental neurotoxins that might cause Parkinson’s disease (Uhl, 1991) that is important for cognitive functioning (Brozoski et al., 1979; Simon et al., 1980). In the prelimbic division of the rat prefrontal cortex (PFC) (Krettek and Price, 1977), dopamine appears to undergo less regulation by DAT-mediated re-uptake when compared with the striatum, as evidenced by a greater extracellular diffusion distance (Garris et al., 1993; Garris and Wightman, 1994; Cass and Gerhardt, 1995). This difference may result simply from the lower dopamine innervation density in the mesocortical versus the nigrostriatal system. However, an alternative interpretation is that dopamine axons and varicosities in the prelimbic PFC have a lower content of DAT and, hence, a reduced uptake capacity. A similar hypothesis has been suggested for the ventral striatum, where there appear to be fewer dopamine uptake sites compared with the dorsal striatum, despite a comparable innervation density (Marshall et al., 1990; Jones et al., 1996). Moreover, these observations are consistent with the lower immunoreactivity and mRNA signal for DAT in the ventral tegmental area (VTA) as compared with the substantia nigra (Shimada et al., 1992; Ciliax et al., 1995).

We sought to test the hypothesis that the neurochemical profile of dopamine overflow and diffusion in the rat prelimbic PFC is associated with a restricted distribution of the DAT protein within individual dopamine axons. We used an electron microscopic immunocytochemical approach to compare the distribution of DAT protein in the dorsolateral striatum and the deep layers of the prelimbic PFC. The relative specificity of the results obtained in the prelimbic cortex with DAT was assessed by comparison with another PFC region, the anterior cingulate cortex, the superficial layers of which are innervated by a separate
group of dopamine axons (Berger et al., 1991). Finally, as a positive procedural control, the distribution of immunoreactivity for DAT within the deep layers of the prelimbic PFC was compared in adjacent sections to the localization of another marker for dopamine axons, the catecholamine synthetic enzyme tyrosine hydroxylase (TH).

Some of these data have been reported in preliminary form (Sesack et al., 1996).

MATERIALS AND METHODS

Immunocytochemistry. Eleven naive adult male Sprague Dawley rats were anesthetized deeply and perfused transcardially with 10 ml of heparin saline (1000 U/ml), followed by fixative. For 10 rats, the fixative consisted of 30 ml of 3.75% acrolein and 2% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 (PB), followed by 250 ml of 2% paraformaldehyde. To determine whether the degree of DAT immunostaining was dependent on the fixative that was used, we perfused the remaining animal with 500 ml of 4% paraformaldehyde with 0.2% glutaraldehyde. The brains were removed, post-fixed in the final fixative for 30 min, and sectioned at 50 μm on a vibratome. To improve antigenicity and reduce nonspecific immunolabeling, we subsequently treated the sections for 30 min with 1% sodium borohydride (LeCraith and Pickel, 1989) and rinsed them in PB. To reduce further the nonspecific labeling before incubation in primary antibody, we treated sections for 30 min in a blocking solution consisting of 1% bovine serum albumin and 3% normal goat serum in 0.1 M Tris-buffered saline (TBS), pH 7.6. Sections for light microscopy were exposed to 0.4% Triton X-100 to enhance antibody penetration. Steps taken to enhance immunostaining for electron microscopy included the use of rapid freeze–thaw or 0.04% Triton X-100 and, in several experiments, two consecutive night incubations in primary antibody.

The qualitative assessment of DAT immunoreactivity was based on two different primary antibodies: rabbit polyclonal (1:100) and rat monoclonal (1:1000). Both antibodies were directed against the N terminus of the DAT protein (Ciliax et al., 1995; Hersch et al., 1997; Miller et al., 1997) and produced comparable immunocytochemical staining. However, only the rat monoclonal antibody was used in quantitative studies. The specificity of both antibodies was demonstrated by Western blot analysis against cloned transporter expressed in mammalian cells and against the native transporter expressed in brain. Interestingly, this analysis detected abundant DAT protein in the striatum but produced no detectable signal in the frontal cortex. This may have reflected the inclusion not only of the prelimbic and anterior cingulate cortices in the sample but of several cortical divisions that receive only a minor dopamine input (Hersch et al., 1997).

Additional tests for antibody specificity have included immunoprecipitation of digitonin-solubilized striatal DAT binding sites and loss of immunoreactivity in experimental animals after neurotoxic lesion with 6-hydroxydopamine (6-OHDA) or in postmortem human brains as a result of Parkinson's disease (Ciliax et al., 1995; Hersch et al., 1997; Miller et al., 1997). In a further control experiment for the present study the rats were killed and treated for 2 hr with 100 μg/ml of the fusion protein antigen and then tested for immunocytochemical staining.

Because our pilot study found minimal immunoreactivity for DAT in the deep layers of the rat prelimbic PFC (Sesack et al., 1996), it became apparent to localize another marker for dopamine terminals in this region as a positive control for our immunolabeling procedure. To this end, adjacent sections through the prelimbic PFC of three animals were incubated in rabbit anti-TH antiserum (1:1000), obtained commercially from Eugene Tech (Ridgefield Park, NJ). The specificity of this antibody has been established in previous studies (Joh et al., 1973), and the relative selectivity of TH antiserum for cortical dopamine axons, as opposed to norepinephrine fibers, has been documented extensively (Gaspar et al., 1989; Lewis and Sesack, 1997). We also have compared TH and dopamine immunolabeling directly in the prelimbic PFC of rats (Sesack et al., 1995), and our quantitative comparison revealed no difference in the synaptic contacts of these terminals. Furthermore, studies of dopamine β-hydroxylase or norepinephrine immunostaining in rat cortex report that few labeled varicosities form identifiable synapses (Descaries and Umbrici, 1995; Blanchereau et al., 1996), whereas the synaptic incidence for terminals immunolabeled for dopamine or TH is much higher (Van Eden et al., 1987; Seguela et al., 1988; Descaries and Umbrici, 1995; Sesack et al., 1995). Despite this difference in synaptic incidence, the relative size of dopamine versus norepinephrine varicosities is roughly equivalent (Descaries and Umbrici, 1995). Thus, the TH antibodies that we used appear to label preferentially the dopamine terminals in the region that was examined (i.e., deep layers of the prelimbic cortex) where the dopamine innervation markedly exceeded that of norepinephrine (Berger et al., 1976; Lindvall and Björklund, 1984). Nevertheless, we cannot exclude the contribution of a few noradrenergic axons to the sample of TH-immunoreactive profiles.

Sections were incubated in primary antibody for 15 hr at room temperature or for 40 hr at 4°C. The secondary antibodies used were biotinylated goat anti-rabbit IgG (1:400) or donkey anti-rat IgG (1:100). Avidin–biotin–peroxidase complex (Vectorstain Elite, Vector Laboratories, Burlingame, CA) was applied at 1:200 (Hsu et al., 1981). The avidin–biotin–peroxidase immunostaining procedure was chosen because of its sensitivity for low-abundance antigens despite its relatively indiscriminate subcellular localization (Hsu et al., 1981; Chan et al., 1990; Nirenberg et al., 1996). All incubations and rinses were performed in TBS with constant agitation. Bound peroxidase was visualized by the addition of 0.022% 3,3′-diaminobenzidine and 0.003% H2O2 for 5 min.

Sections for light microscopy were slide-mounted, dehydrated, and coverslipped. Sections for electron microscopy were post-fixed in 2% osmium tetroxide in PB, dehydrated via increasing strengths of ethanol and propylene oxide, and plastic-embedded with Epon-812 (Electron Microscopy Sciences, Fort Washington, PA). Small regions within the cortex and striatum were cut from these thick sections and glued onto blocks of embedding plastic. The regions of interest were trimmed further (Fig. 1) and then sectioned at 60–70 nm on an ultramicrotome. The ultrathin sections were collected on copper mesh grids and stained with uranyl acetate and lead citrate before being viewed in a Zeiss 902 transmission electron microscope (Oberkochen, Germany).

Quantitative image analysis. The approximate density and morphological features of fibers immunoreactive for the DAT were assessed qualitatively, and a quantitative approach was used to further estimate the relative distribution of DAT protein to varicose or intervaricose seg-
ments of axons. The quantitative assessment was based on the measurement of profile diameter, keeping in mind that, although diameter is not an index of morphology, small profiles have a greater probability of being axons, whereas large profiles have a greater probability of being varicosities.

The electron microscopic results from six rats with the best morphology and most robust staining with the rat anti-DAT antibody were quantified in three regions (Fig. 1): dorsolateral striatum, layers I–III of the rostral, dorsal anterior cingulate cortex, and layers V–VI of the prelimbic cortex (Krettek and Price, 1977). The cortical layers that were examined were chosen on the basis of the known distribution of dopamine fibers in the rat supragenual and pregenual mesocortical projections, respectively (Berger et al., 1991). For three of the six rats, adjacent thick sections through the prelimbic PFC were stained with rabbit anti-TH antibody and examined both qualitatively and quantitatively. The cingulate cortex was not included in this analysis of TH immunolabeling.

One to two thick tissue sections per region per animal were examined, and the surface of the tissue where antibody penetration was maximal was sampled at random. The specific immunoperoxidase reaction product for DAT was identified as an electron-dense flocculent precipitate that accumulated within the cytoplasm, along the inner plasmalemmal surface, and along the outer membranes of organelles, including synaptic vesicles. Such flocculent precipitate can be distinguished from other electron dense structures in the tissue, even when it is present at low levels (Sesack et al., 1994; Delle Donne et al., 1996, 1997). Furthermore, this flocculent product was not observed in presumed unlabeled structures in the immediately adjacent neuropil or in any structures viewed at greater depths from the surface.

At least 40 profiles immunoreactive for DAT (all regions) or TH (prelimbic cortex) were photographed at 13,000x and printed at 2.5x enlargement. Immunolabeled profiles were identified as varicose or intervaricose portions of axons (Peters et al., 1991) on the basis of their small size, location in fields of small unmyelinated axons, presence of synaptic vesicles, and/or occasional formation of synapses on spines or dendrites. Compared with intervaricose axon segments, varicosities were typically larger, contained more vesicles, and were more likely to form synapses. A few profiles contained small patches of weak immunoreaction product that were considered to be nonspecific. These profiles were excluded from analysis, as were densely immunolabeled profiles that did not have well delineated boundaries. The remaining profiles were numbered sequentially on the micrographs from upper left to lower right, and a random number generator was used to select 30 profiles per region per animal. This number of profiles was determined from a pilot study to be the minimum sample size per animal needed to detect a 30% difference among means between regions or markers with 80% power, using a Student’s t test. In total, 180 immunoreactive profiles per region for DAT and 90 profiles for TH in the prelimbic PFC were selected.

The electron micrographic negatives were scanned by a digital camera into an image analysis system (Advanced Imaging Concepts, Princeton, NJ). The immunoreactive processes were traced by a single investigator, and a set of rules was established to minimize variability in the tracing. For example, (1) when profiles were labeled heterogeneously, only the portions that contained immunoreaction product were traced; (2) when the plasma membrane was clearly visible, tracing was done directly along the membrane; (3) when the plasma membrane was obscured slightly by immunoglobulin or plane of section, tracing was done along the outer edge of the immunoreactivity; (4) when immunolabeled profiles were apposed to each other (primarily in the striatum), tracing was done along the inner edge of each apposed membrane so that the traced profiles did not merge.

An unbiased, computerized algorithm was used to determine the maximum diameter of each traced profile along its short axis by counting in one pixel layer at a time from the perimeter and forming a “topographic map” of the profile (Fig. 2). For immunoreactive profiles with eccentricity large enough that the maximum diameter along the axis was greater than the perimeter of the profile, the data were analyzed statistically by a two-way ANOVA, with the main effects being either region and animal for DAT or marker and animal for DAT versus TH. The interactions between main effects were determined also, and post hoc analyses were performed with Tukey’s studentized range test.

**RESULTS**

**Light microscopy**

Light microscopic examination of the dorsolateral striatum revealed immunoreactivity for DAT that was localized densely and diffusely to the neuropil surrounding unlabeled perikarya and bundles of myelinated axons (Fig. 3A). The density of the peroxidase reaction product precluded the visualization of individual fibers. Examination of the same striatal region in sections incubated in antibody preadsorbed with the DAT antigen revealed no detectable immunoreactivity (Fig. 3B).

In the rostral portion of the anterior cingulate cortex, DAT-immunoreactive fibers were localized diffusely throughout layers I–III and often were clustered densely within layer III (Fig. 3C). DAT-immunoreactive axons in these clusters exhibited evidence of both branching and varicose beading. In the adjacent prelimbic division of the PFC, DAT-immunoreactive fibers were markedly sparse within the deep layers V–VI, even when the tissue was viewed with differential interference contrast (DIC) optics (Fig. 3D). A few of the DAT-immunoreactive axons were beaded or branched, whereas the remainder appeared to be fibers en passant. This weak immunolabeling in the prelimbic PFC was observed despite the use of two night incubations in primary antibody that contained a high concentration of detergent to enhance permeation. Furthermore, this low level of DAT immunoreactivity also was observed in the more ventral infralimbic division of the PFC, although this region was not explored further during this investigation.

**Electron microscopy**

By electron microscopic examination of the dorsolateral striatum, dense peroxidase immunoreactivity for the DAT was expressed abundantly in axon varicosities and preterminal axons (Fig. 4A) that exhibited features characteristic of dopamine fibers: lack of myelination, small size, content of mostly clear synaptic vesicles, and occasional formation in single sections of punctate symmetric synapses on spines or distal dendrites (Pickel et al., 1981; Bouyer et al., 1986). Such flocculent precipitate can be distinguished from other electron dense structures in the tissue, even when it is present at low levels (Sesack et al., 1994; Delle Donne et al., 1996, 1997).
Figure 3. Light micrographs illustrating peroxidase immunoreactivity for DAT in the rat forebrain. A, In the dorsolateral striatum, dense peroxidase product for DAT is localized to the neuropil immediately beneath the corpus callosum (cc). Perikarya (asterisks) and bundles of myelinated axons (m) are unlabeled. B, No DAT immunoreactivity is detected in the same striatal region of sections incubated in primary antibody preadsorbed with the DAT antigen. C, In the rostral portion of the anterior cingulate cortex, a dense cluster of DAT-immunoreactive fibers is visualized in layer III. These presumed axons exhibit the branching (small arrows) and beading (large arrows) that are characteristic of terminal fibers. D, In layer VI of the prelimbic cortex from the same section as that shown in C, sparse fibers immunoreactive for DAT are observed. Although some are beaded or branched, others appear to be fibers of passage (open arrows) exiting the white matter. In A–D, up is dorsal and left is medial. Scale bar, 150 μm.
Figure 4. Electron micrographs illustrating peroxidase immunoreactivity for DAT in the rat forebrain. A. In the dorsolateral striatum, immunoreactivity for DAT is localized to axon varicosities (DAT-v) that contain numerous synaptic vesicles surrounded by dense peroxidase product. One immunoreactive varicosity appears to form a small symmetric synapse on a dendritic process (thick arrow). B. In the cingulate cortex, DAT immunoreactivity is observed both in a varicose structure and in small axon-like profiles (DAT-a, thin arrows), some of which contain synaptic vesicles. C. In the prelimbic cortex, immunoreactivity for DAT is seen almost exclusively in small axon-like profiles (thin arrows). Immunonegative structures that exhibit similar size and morphology are indicated at the open arrows. D. DAT immunolabeling in the prelimbic cortex is visualized clearly in an axon cut longitudinally (thin arrow), whereas the contiguous varicosity forms a synapse on a dendritic spine (thick arrow) but otherwise is unlabeled for DAT. Scale bar, 0.5 μm.
et al., 1984; Freund et al., 1984; Descarries et al., 1996). In the superficial layers of the anterior cingulate cortex, similar immunoreactive profiles were observed. However, small-diameter vesicle-containing processes that probably represented intervaricose axon segments appeared qualitatively to contain a lower density of DAT immunoreactivity (Fig. 4B).

In the deep layers of the prelimbic PFC, peroxidase immunolabeling for the DAT was localized almost exclusively to the intervaricose segments of axons (Fig. 4C,D) and was qualitatively less dense than that observed in the dorsolateral striatum. Occasionally, immunoreactive axons were sectioned longitudinally, and it was possible to visualize the varicosities to which they gave rise. In such instances, the varicose portions of the axons invariably were devoid of DAT immunoreactivity, whereas the intervaricose regions contained a moderate density of peroxidase product (Fig. 4D). Consistent findings were obtained regardless of the fixative used, the primary antibody used (rat monoclonal, Fig. 4C or rabbit polyclonal, Fig. 4D), the use of one or two night incubations in antibody, or the use of Triton X-100 detergent versus freeze–thaw to enhance antibody penetration. Peroxidase labeling in striatal and cortical sections virtually was eliminated by preadsorption of the primary antibody with the DAT antigen.

In adjacent sections of the prelimbic PFC, immunoreactivity for TH was detected in numerous axons and varicosities in the deep layers, some of which formed synapses on spines and small dendrites (Fig. 5).

Quantitative analysis
By quantitative analysis over all of the animals, the mean diameter (± SD) of DAT-immunoreactive profiles was smaller in the prelimbic cortex (0.137 ± 0.049) than in the anterior cingulate cortex (0.180 ± 0.074) or the dorsolateral striatum (0.218 ± 0.084). Furthermore, this same pattern of mean diameter being smallest in the prelimbic cortex, larger in the cingulate cortex, and largest in the striatum was observed for each of the six animals. By two-way ANOVA, there was a significant overall effect of region (p < 0.0001) and no effect of animal. However, a significant interaction between region and animal (p < 0.012) suggested that some of the regional effect might be explained by animal differences. Because the region effects were similar for all animals, pairwise comparisons of main effects for regions were conducted with Tukey’s studentized range test, with a simultaneous significance of p < 0.05. All three regions were found to be significantly different from each other.

To explore further the nature of the interaction between region and animal, we did post hoc analyses with Tukey’s procedure (again, with simultaneous significance of p < 0.05) on all 18 animal–region comparisons. These comparisons revealed that a significant difference in diameter between the prelimbic cortex and the striatum occurred in all six animals. For the anterior cingulate cortex, significant differences with the prelimbic cortex were detected in three of the six animals and with the striatum in two of the six animals. However, it must be reemphasized that the same pattern of regional variation in mean diameter occurred for each animal, regardless of whether these differences reached statistical significance with the sample size chosen for this analysis.

Within the deep layers of the prelimbic PFC, DAT-immunoreactive profiles were smaller in mean diameter than those labeled in adjacent sections for TH (0.215 ± 0.088). By two-way ANOVA there was an overall significant effect of marker (p < 0.0001), with no effect of animal and no interaction effect.

In addition to the statistical analysis of means, it was considered useful to provide a full description of the data by using a frequency histogram of all 180 observations per region for DAT and all 90 observations for TH in the prelimbic PFC (Fig. 6). From this perspective a majority of DAT-immunoreactive profiles in the prelimbic cortex were of small diameter, whereas a greater proportion of DAT-immunoreactive profiles in the cingulate cor-
tex and striatum was of larger diameter. The latter was also true for TH-immunolabeled profiles in the prelimbic cortex.

In previous studies of dopamine axons in forebrain regions, profiles smaller than 0.2 μm typically have been considered pre-terminal axons and often have been excluded from analysis of varicosities (Bouyer et al., 1984; Freund et al., 1984; Séguela et al., 1988; Smiley and Goldman-Rakic, 1993; Descarries et al., 1996). Although we applied no such exclusion criterion to our analysis, it was of interest to determine the proportion of DAT-immunoreactive profiles in the present study that had a diameter ≥0.2 μm. Across all of the animals, only 12% (range per animal, 3–20%) of DAT-immunoreactive profiles in the prelimbic cortex met this criterion, whereas 35% (range, 17–53%) of those in the cingulate cortex and 56% (range, 50–67%) of those in the striatum were of this diameter or larger. Similarly, in the prelimbic cortex, 51% (range, 50–53%) of profiles immunoreactive for TH were ≥0.2 μm in diameter. These differences across regions and within the prelimbic PFC for the two markers were significantly different (p < 0.0001) by Fisher’s exact test (Matthews and Farewell, 1996). Similar regional and marker differences were obtained when the criterion was set at 0.23 or 0.29 μm. In the latter case, only a single DAT-immunoreactive profile in the prelimbic PFC had a diameter that exceeded 0.29 μm.

**DISCUSSION**

The combined light and electron microscopic results suggest that dopamine axon varicosities in the rat prelimbic PFC express relatively low levels of DAT protein and a localization of DAT that is distant from synaptic release sites. These findings are consistent with observations of low DAT protein and mRNA in some VTA dopamine neurons and suggest that individual dopamine cells are capable of selectively targeting this important protein to different locations within the axon. Furthermore, the results agree with neurochemical studies reporting greater extracellular diffusion of dopamine in the prelimbic PFC as compared with the dorsal striatum. Although the data appear to support a
greater paracrine role for cortical dopamine, the actual sphere of influence of dopamine in the PFC may be limited by the low density of its receptors. These observations and hypotheses are depicted schematically in Figure 7.

**Methodology and comparison to published findings**

*Light microscopy*

The present light microscopic distribution of DAT compares well with previous immunocytochemical studies showing a dense localization to the striatum and weaker labeling of cortex (Ciliax et al., 1995; Freed et al., 1995; Nireenberg et al., 1996). However, the cortical pattern of DAT labeling does not match previous accounts of dopamine axons that used other markers (Descaries et al., 1987; Van Eden et al., 1987; Séguéla et al., 1988; Berger et al., 1991). Although the distribution of DAT in the superficial layers of the anterior cingulate cortex matches the innervation by dopamine axons, the DAT fiber density in the deep layers of the prelimbic and infralimbic cortices underestimates the known distribution of dopamine axons in these areas. These observations are supported by biochemical reports of low DAT protein levels in the medial PFC (Vaughan et al., 1996) and by autoradiographic studies describing fewer DAT sites in the deep layers of the prelimbic cortex versus the cingulate cortex or subcortical sites (Scatton et al. (1985); Coulter et al. (1995); but see Descaries et al. (1987)). These findings suggest that the density of DAT in...
terminal regions reflects differences in the dopamine cells of origin, because the superficial layers are innervated by the substantia nigra whereas the deep layer input derives from the VTA (Berger et al., 1991).

The potential contribution of technical factors to the sparsity of DAT in the prelimbic PFC seems unlikely, because the antibody incubation conditions produced robust labeling of the striatum and adjacent cingulate cortex in the same animals. It is possible that the dopamine neurons projecting to the prelimbic PFC express a different transporter gene product. However, a second DAT gene has not yet been identified (Uhl, 1992; Lorang et al., 1994; Bannon et al., 1995). Moreover, recent biochemical evidence suggests that the DAT protein in the striatum, accumbens, PFC, and midbrain is the product of a single gene (Vaughan et al., 1996). Alternatively, the DAT in mesoprefrontal dopamine neurons may be modified biochemically after translation in a manner that prevents antibody recognition. For example, differences in phosphorylation or glycosylation of the DAT (Lew et al., 1992; Vaughan et al., 1996; Huff et al., 1997) might alter both function and antibody binding. However, to date, neither phosphorylation nor glycosylation has been shown to alter recognition by DAT antibodies directed against four different epitopes (Patel et al., 1994; Vaughan et al., 1996; Huff et al., 1997).

Perhaps the most parsimonious explanation for the sparse distribution of DAT immunoreactivity in the prelimbic PFC is the presence of dopamine axons, for which the content of DAT protein is below detectable levels. This suggestion is consistent with reports of neurons that express mRNA for TH, but not DAT (Augood et al., 1993; Lorang et al., 1994), in the medial VTA regions that project to the prelimbic PFC (Swanson, 1982; Berger et al., 1991). A similar observation also has been made in the primate VTA (Haber et al., 1995). Immunoreactivity for the DAT is also weak in the medial VTA (Ciliax et al., 1995), suggesting that reduced somatodendritic localization of DAT protein accompanies sparse levels of DAT in axons. Low levels of DAT also have been reported in the dopamine neurons of the hypothalamus, retina, and olfactory bulb (Shimada et al., 1992; Cerruti et al., 1993; Lorang et al., 1994; Ciliax et al., 1995). Moreover, our results are consistent with a preliminary report that some cortical serotonin axons lack immunoreactivity for the serotonin transporter (Axt et al., 1995).

**Electron microscopy**

In the present study the ultrastructural features of varicosities labeled for DAT in the striatum and cingulate cortex match those previously described with uptake of radiolabeled transmitter (Descarries et al., 1987) or antibodies against DAT (Niremberg et al., 1996; Hersch et al., 1997), dopamine (Descarries et al., 1996), or TH (Pickel et al., 1981; Bouyer et al., 1984; Freund et al., 1984). However, in the prelimbic PFC the almost exclusive distribution of DAT to small-diameter intervaricose axon segments is discrepant with other markers of dopamine fibers (listed above), which frequently label varicosities as well as the intervaricose portions of axons (Descarries et al., 1987; Van Eden et al., 1987; Séguela et al., 1988; Sesack et al., 1995).

Although the use of heavy metal counterstaining may have prevented the detection of low levels of immunoperoxidase product for DAT in the prelimbic PFC, the observation in longitudinal sections that the varicose portions of otherwise immunoreactive axons contained no detectable DAT labeling argues that technical factors did not contribute significantly to the ultrastructural findings. It also should be noted that the failure to localize DAT to varicosities within the prelimbic PFC occurred despite the use of the sensitive avidin–biotin immunoperoxidase method (Hsu et al., 1981) and the ability of peroxidase product to diffuse short distances within labeled structures (Courtoy et al., 1983). Although immunogold methods provide better subcellular localization and have been used to demonstrate a perisynaptic localization of DAT in the striatum (Nirenberg et al., 1996; Hersch et al., 1997), these approaches were not chosen for the present study because of their low sensitivity (Chan et al., 1990).

The distribution of DAT to intervaricose axon segments in the prelimbic PFC suggests that this protein is localized primarily at a distance from varicose sites of release. However, dopamine axons in the striatum sometimes exhibit synapses along intervaricose regions (Freund et al., 1984; Groves et al., 1994). Although we have not observed such occurrences in our cortical studies and none has been reported to date in the rodent or primate PFC (Séguela et al., 1988; Smiley and Goldman-Rakic, 1993), a complete serial reconstruction of dopamine axons is required to address this issue fully. Furthermore, the widely held view that transmitter release occurs via vesicle exocytosis at active zones has not been proven conclusively in the CNS (Smith and Augustine, 1988). Thus, the exact spatial relationship between sites of dopamine release and re-uptake in individual cortical axons remains to be determined.

**Functional implications**

Several neurochemical observations are consistent with the observed paucity of DAT in the rat prelimbic PFC. For example, both endogenously released (Garris et al., 1993; Garris and Wightman, 1994) and exogenously applied (Cass and Gerhardt, 1995; Lee et al., 1996) dopamine exhibit greater extracellular diffusion and slower clearance in the PFC as compared with other forebrain areas. Although a direct comparison between the prelimbic and anterior cingulate cortices has not been made, Garris and colleagues (1993) did show that electrical stimulation evoked a voltammetric signal for dopamine only in the ventral, and not the dorsal, region of the anteromedial cortex. Investigators also have noted that the ratio of dopamine in dialysate to whole tissue levels is considerably higher in the PFC than in the striatum or nucleus accumbens, suggesting that the cortex expresses a proportionally greater amount of extracellular dopamine relative to intraneuronal stores (Sharp et al., 1986; Maisonneuve et al., 1990; Garris et al., 1993).

There are several potential explanations for these findings. Compared with other forebrain dopamine systems, mesocortical dopamine neurons may have a greater capacity for release (Sharp et al., 1986; Hoffman et al., 1988; Garris et al., 1993), consistent with their higher firing rates, more efficient depolarization–release coupling, and absence of autoreceptor inhibition of synthesis (Chiody et al., 1984; White and Wang, 1984; Wolf et al., 1986; Hoffman et al., 1988). Other contributing factors could include variations in the levels of metabolic enzymes or extracellular tortuosity factors that affect diffusion (Nicholson, 1995). However, studies in mice lacking DAT gene expression (Giros et al., 1996) suggest that dopamine synthesis, autoreceptor density, and other factors have less impact on extracellular dopamine than has the DAT protein itself. Thus, the sparsity of DAT in the PFC might contribute to higher extracellular levels, as compared with the striatum, if each cortical dopamine axon contains proportionally less DAT protein and/or if the DAT is localized further from the release sites.
Other findings that support this view include the reportedly reduced efficacy of selective dopamine uptake blockers in the PFC as compared with subcortical regions (Carboni et al., 1990; Cenci et al., 1992; Pozzi et al., 1994). Cocaine is also less potent at blocking dopamine uptake into synaptosomes or tissue slices from the PFC than those from the striatum (Hadfield and Nugent, 1983; Izenwasser et al., 1990; Elsworth et al., 1993). Furthermore, at all systemic doses, cocaine produces a less profound increase in extracellular dopamine in the PFC than in the striatum (Moghaddam and Bunney, 1989).

Despite the paucity of DAT in the prelimbic PFC, additional mechanisms do exist to terminate the actions of dopamine, including diffusion, extraneuronal metabolism (Sharp et al., 1986; Maisonneuve et al., 1990; Karoum et al., 1994), and uptake by proteins other than the DAT. Of particular note, dopamine is the preferred substrate for the norepinephrine transporter (NET) (Bannon et al., 1995), and dopamine is known to be taken up into norepinephrine axons in the PFC (Carboni et al., 1990; Izenwasser et al., 1990; Elsworth et al., 1993; Pozzi et al., 1994; Tanda et al., 1994; Gresch et al., 1995; Lee et al., 1996). On the basis of these observations it has been suggested that the clinical actions of antidepressant drugs that block the NET may include an increase in dopamine levels in the PFC (Carboni et al., 1990; Pozzi et al., 1994; Tanda et al., 1994). However, despite the availability of this mechanism, the PFC still exhibits a reduced capacity for dopamine clearance (Garris et al., 1993; Garris and Wightman, 1994; Cass and Gerhardt, 1995), perhaps because of the sparsity of norepinephrine terminals in the deep layers of the prelimbic PFC (Berger et al., 1976; Lindvall and Björklund, 1984). In support of this suggestion, the NET appears to play a greater role in clearing exogenously applied dopamine in the dorsal (i.e., cingulate) than in the ventral (i.e., prelimbic) PFC (Cass and Gerhardt, 1995).

Conclusions

It has been argued that dopamine primarily serves a paracrine role in the PFC (Garris and Wightman, 1994), although other observations argue against this hypothesis. First, as discussed above, there are multiple mechanisms for dopamine clearance in the cortex, including the sparse DAT protein that is present. Second, a significant number of dopamine varicosities form contacts with the sparse DAT protein that is present. Furthermore, at all systemic doses, dopamine produces a less pronounced increase in extracellular dopamine in the PFC than in the striatum (Moghaddam and Bunney, 1989).

Despite the paucity of DAT in the prelimbic PFC, additional mechanisms do exist to terminate the actions of dopamine, including diffusion, extraneuronal metabolism (Sharp et al., 1986; Maisonneuve et al., 1990; Karoum et al., 1994), and uptake by proteins other than the DAT. Of particular note, dopamine is the preferred substrate for the norepinephrine transporter (NET) (Bannon et al., 1995), and dopamine is known to be taken up into norepinephrine axons in the PFC (Carboni et al., 1990; Izenwasser et al., 1990; Elsworth et al., 1993; Pozzi et al., 1994; Tanda et al., 1994; Gresch et al., 1995; Lee et al., 1996). On the basis of these observations it has been suggested that the clinical actions of antidepressant drugs that block the NET may include an increase in dopamine levels in the PFC (Carboni et al., 1990; Pozzi et al., 1994; Tanda et al., 1994). However, despite the availability of this mechanism, the PFC still exhibits a reduced capacity for dopamine clearance (Garris et al., 1993; Garris and Wightman, 1994; Cass and Gerhardt, 1995), perhaps because of the sparsity of norepinephrine terminals in the deep layers of the prelimbic PFC (Berger et al., 1976; Lindvall and Björklund, 1984). In support of this suggestion, the NET appears to play a greater role in clearing exogenously applied dopamine in the dorsal (i.e., cingulate) than in the ventral (i.e., prelimbic) PFC (Cass and Gerhardt, 1995).

Conclusions

It has been argued that dopamine primarily serves a paracrine role in the PFC (Garris and Wightman, 1994), although other observations argue against this hypothesis. First, as discussed above, there are multiple mechanisms for dopamine clearance in the cortex, including the sparse DAT protein that is present. Second, a significant number of dopamine varicosities form conventional synapses in both the rat (Séguela et al., 1988) and monkey (Smiley and Goldman-Rakic, 1993; Sesack et al., 1995) PFC and exhibit specificity in their synaptic targets (Lewis et al., 1996). Finally, overall dopamine receptor expression is substantially lower in the cortex, as compared with the striatum, and many dopamine receptor subtypes exhibit specificity in their neuronal distribution (Levey et al., 1993; Bergson et al., 1995; Mrzljak et al., 1996). Such a profile would not be predicted for a transmitter with widely distributed actions on multiple cell types.

An alternative hypothesis is that synaptically released dopamine produces the greatest functional impact, with additional extrasynaptic actions occurring only over short distances. Establishing the validity of this hypothesis will require exact knowledge about the concentration gradients of extracellular dopamine and the location and affinity of receptors relative to release sites. However, if this speculation has credence, it suggests that mesoprefrontal dopamine neurons may express little DAT protein because it is not critical for terminating the actions of dopamine and because it is economical to avoid the energy-requiring process of re-uptake.

REFERENCES

Delle Donne KT, Sesack SR, Pickel VM (1997) Ultrastructural immu-
norectochemochemical localization of the dopamine D_{2} receptor within GABAergic neurons of the rat striatum. Brain Res 746:239–255.


Sesack et al. • Sparse Dopamine Transporter in Rat Prefrontal Cortex J. Neurosci., April 1, 1998, 18(7):2697-2708 2707